Anastasia Marvaki
Thessaloniki, ESYE12, Greece
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Ravulizumab for treatment of paroxysmal nocturnal hemoglobinuria during pregnancy.
Journal: Blood advances
Published: December 01, 2025
Ravulizumab for Treatment of Paroxysmal Nocturnal Hemoglobinuria During Pregnancy.
Journal: Blood advances
Published: December 01, 2025
Treosulfan-Based Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Other Myeloid Malignancies.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 24, 2025
Secondary Acute Myeloid Leukemia (sAML): Similarly Dismal Outcomes of AML After an Antecedent Hematologic Disorder and Therapy Related AML.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 16, 2021
Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data.
Journal: Hematological oncology
Published: June 03, 2019
BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma.
Journal: Bone marrow transplantation
Published: October 24, 2018
Donor EBV at the time of hematopoietic cell transplantation: Is it time to adopt molecular assays?
Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
Published: December 23, 2017
Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
Journal: Leukemia & lymphoma
Published: March 12, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026